ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today ...
Medications targeting the neonatal fragment crystallizable receptor have gained attention due to multiple recent FDA ...
Generic comorbidity measures may not reflect the unique clinical profile of people with MS, hitting a predictive ceiling.
Biogen (NASDAQ:BIIB) executives said the company ended 2025 “slightly above the upper end” of its guidance, pointing to ...
Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...
A research team led by Professor Wang Hongzhi from the Hefei Institute of Physical Science of the Chinese Academy of Sciences has developed a multi-stage, dual-domain, progressive network with ...
For individuals with MS, proteomic analysis offers insight into the role disease progression plays in affecting both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results